粪便免疫化学检测与结肠镜在结直肠癌筛查中的疗效与成本效益:系统综述与荟萃分析
该系统综述与荟萃分析比较了粪便免疫化学检测(FIT)与结肠镜在平均风险人群结直肠癌筛查中的疗效与成本效益。多数成本效益研究表明 annual 或 biennial FIT 相比每10年一次结肠镜具有成本节约或极佳成本效益。
要点
- FIT筛查参与率高于结肠镜(41.6% vs 21.9%)。
- FIT对任何腺瘤和进展期腺瘤检出率低于单次结肠镜。
核心结论
- FIT对结直肠癌的检出率可能与单次结肠镜相似,但对任何腺瘤和进展期腺瘤的检出率低于单次结肠镜。
- 年度或双年度FIT相比每10年一次结肠镜似乎非常具有成本效益或可节约成本。
- 这些发现至少部分表明FIT在平均风险人群结直肠癌筛查中不劣于结肠镜,但需谨慎对待并进一步确认。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase和National Health Services Economic Evaluation Database。
- 共纳入6项随机对照试验和17项成本效益研究。
- 使用风险比(RR)评估FIT与结肠镜组间结直肠肿瘤检出率差异,采用随机效应模型合并RR。
- 计算增量成本效益比(ICER)评估FIT与结肠镜的成本效益。
主要发现
- FIT组参与率高于结肠镜组(41.6% vs 21.9%)。
- FIT对任何腺瘤和进展期腺瘤的检出率低于单次结肠镜。
- 多数纳入的成本效益研究表明,与每10年一次结肠镜相比,年度FIT(13/15)或双年度FIT(5/6)具有成本节约(ICER < $0)或非常具有成本效益($0 < ICER ≤ $25000/质量调整生命年)。
关键数值与推荐
- FIT组参与率41.6%,结肠镜组21.9%。
- 年度FIT成本效益研究13/15显示成本节约或非常具有成本效益。
- 双年度FIT成本效益研究5/6显示成本节约或非常具有成本效益。
- 成本效益阈值:ICER < $0为成本节约,$0 < ICER ≤ $25000/质量调整生命年为非常具有成本效益。
临床怎么用
- 在平均风险人群结直肠癌筛查中,FIT可作为结肠镜的替代选择,尤其考虑其较高的参与率。
- 年度或双年度FIT方案相比每10年结肠镜可能更具成本效益。
- 需注意FIT对腺瘤的检出率低于结肠镜,筛查策略选择应结合人群特点和资源条件。
局限性
- 研究结果需谨慎对待并需进一步确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The fecal immunochemical test (FIT) and colonoscopy are the most commonly used strategies for colorectal cancer (CRC) screening worldwide. We aimed to compare their efficacy and cost-effectiveness in CRC screening in an average-risk population. METHODS: PubMed, Embase, and National Health Services Economic Evaluation Database were searched. Risk ratio (RR) was used to evaluate the differences in detection rates of colorectal neoplasia between FIT and colonoscopy groups. A random-effects model was used to pool RRs. Incremental cost-effectiveness ratios (ICERs) were calculated to evaluate the cost-effectiveness of FIT versus colonoscopy. RESULTS: Six randomized controlled trials and 17 cost-effectiveness studies were included. The participation rate in the FIT group was higher than that in the colonoscopy group (41.6% vs 21.9%). In the intention-to-treat analysis, FIT had a detection rate of CRC comparable with colonoscopy (RR, .73; 95% confidence interval, .37-1.42) and lower detection rates of any adenoma and advanced adenoma than 1-time colonoscopy. Most included cost-effectiveness studies showed that annual (13/15) or biennial (5/6) FIT was cost-saving (ICER < $0) or very cost-effective ($0 < ICER ≤ $25000/quality-adjusted life-year) compared with colonoscopy every 10 years. CONCLUSIONS: FIT may be similar to 1-time colonoscopy in the detection rate of CRC, although it has lower detection rates of any adenoma and advanced adenoma than 1-time colonoscopy. Furthermore, annual or biennial FIT appears to be very cost-effective or cost-saving compared with colonoscopy every 10 years. These findings indicate, at least partly, that FIT is noninferior to colonoscopy in CRC screening in an average-risk population. Our findings should be treated with caution and need to be further confirmed.
引用
- Zhong GC, Sun WP, Wan L, et al. Efficacy and cost-effectiveness of fecal immunochemical test versus colonoscopy in colorectal cancer screening: a systematic review and meta-analysis. Gastrointest Endosc. 2019. PMID: 31790657. doi:10.1016/j.gie.2019.11.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。